[HTML][HTML] Oral Alpha-Lipoic Acid to Prevent Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Trial
Y Guo, D Jones, JL Palmer, A Forman… - Supportive care in …, 2014 - ncbi.nlm.nih.gov
Objectives Chemotherapy-induced peripheral neuropathy is frequently a dose-limiting factor
in cancer treatment and may cause pain and irreversible function loss in cancer survivors …
in cancer treatment and may cause pain and irreversible function loss in cancer survivors …
Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.
Y Guo, D Jones, J Palmer, A Forman… - Supportive Care in …, 2014 - search.ebscohost.com
Objectives: Chemotherapy-induced peripheral neuropathy is frequently a dose-limiting
factor in cancer treatment and may cause pain and irreversible function loss in cancer …
factor in cancer treatment and may cause pain and irreversible function loss in cancer …
Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.
Y Guo, D Jones, JL Palmer, A Forman… - Supportive Care in …, 2013 - europepmc.org
Objectives Chemotherapy-induced peripheral neuropathy is frequently a dose-limiting factor
in cancer treatment and may cause pain and irreversible function loss in cancer survivors …
in cancer treatment and may cause pain and irreversible function loss in cancer survivors …
Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.
Y Guo, D Jones, J Palmer, A Forman… - Supportive Care in …, 2014 - search.ebscohost.com
Objectives: Chemotherapy-induced peripheral neuropathy is frequently a dose-limiting
factor in cancer treatment and may cause pain and irreversible function loss in cancer …
factor in cancer treatment and may cause pain and irreversible function loss in cancer …